Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6D7N8)

Drug Name
Propylthiouracil Drug Info
Synonyms
propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil; Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile
Therapeutic ClassAntithyroid Agents
Cross-matching ID
PubChem CID
657298
ChEBI ID
CHEMBL1518
CAS Number
CAS 51-52-5
TTD Drug ID
D00MIN
ACDINA Drug ID
D00566

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.84 0.00e+0 113/158 (71.52%) MRPS16;MRPL13;RPL26;...
Oxidative phosphorylation 2.78 0.00e+0 93/133 (69.92%) COX7B;ATP5MG;ATP5PD;...
Parkinson disease 2.58 0.00e+0 176/249 (70.68%) CYCS;COX7B;PSMA3;...
Proteasome 2.46 0.00e+0 44/46 (95.65%) PSMA3;PSMA6;PSME1;...
Huntington disease 2.41 0.00e+0 233/306 (76.14%) CYCS;COX7B;PSMA3;...
Pyruvate metabolism 2.31 0.00e+0 41/47 (87.23%) DLD;ADH5;ALDH3A2;...
Amyotrophic lateral sclerosis 2.17 0.00e+0 267/364 (73.35%) CYCS;COX7B;PSMA3;...
Prion disease 2.14 0.00e+0 209/273 (76.56%) CYCS;COX7B;PSMA3;...
Thermogenesis 2.10 0.00e+0 173/232 (74.57%) COX7B;ATP5MG;ATP5PD;...
Diabetic cardiomyopathy 2.07 0.00e+0 162/203 (79.8%) COX7B;ATP5PD;ATP5F1C;...
Alzheimer disease 2.00 0.00e+0 279/369 (75.61%) CYCS;COX7B;PSMA3;...
Pathways of neurodegeneration 1.99 0.00e+0 354/475 (74.53%) CYCS;COX7B;PSMA3;...
Non-alcoholic fatty liver disease 1.97 5.11e-4 126/155 (81.29%) CYCS;CDC42;COX7B;...
Glycolysis / Gluconeogenesis 1.94 9.50e-4 56/67 (83.58%) PGAM1;DLD;ADH5;...
Protein export 1.92 8.86e-4 17/23 (73.91%) OXA1L;SEC61B;SPCS1;...
Citrate cycle (TCA cycle) 1.89 1.25e-3 30/30 (100%) DLD;SUCLG1;MDH1;...
DNA replication 1.86 1.56e-3 34/36 (94.44%) MCM6;POLE2;PCNA;...
Mineral absorption 1.66 2.66e-2 48/60 (80%) MT1E;MT1F;STEAP1;...
RNA polymerase 1.62 3.95e-2 23/31 (74.19%) POLR2L;POLR2K;POLR2G;...
Arginine and proline metabolism 1.62 3.76e-2 39/50 (78%) AOC1;ALDH3A2;GOT1;...
Collecting duct acid secretion 1.61 3.83e-2 22/27 (81.48%) CA2;ATP6V1A;ATP6V1B1;...
Glutathione metabolism 1.61 3.66e-2 43/57 (75.44%) GPX3;ANPEP;IDH2;...
Tryptophan metabolism 1.61 3.58e-2 35/42 (83.33%) AOC1;DLD;ALDH3A2;...
Proximal tubule bicarbonate reclamation 1.61 3.49e-2 21/23 (91.3%) CA2;MDH1;PCK1;...
Chagas disease -1.75 4.95e-2 93/102 (91.18%) IL10;TLR4;CD3D;...
Mucin type O-glycan biosynthesis -1.86 2.43e-2 20/36 (55.56%) B4GALT5;GCNT1;GALNT11;...
Phosphatidylinositol signaling system -1.91 1.42e-2 82/97 (84.54%) DGKG;INPP1;INPP5F;...
Chemokine signaling pathway -1.96 8.49e-3 163/192 (84.9%) FOXO3;RAC1;PARD3;...
Amoebiasis -2.01 3.54e-3 99/102 (97.06%) PLCB4;TGFB1;PIK3CA;...
Type II diabetes mellitus -2.04 4.72e-3 42/46 (91.3%) CACNA1B;PRKCE;MAPK9;...
Viral protein interaction with cytokine and cytokine re... -2.09 7.08e-3 84/100 (84%) TNFRSF1A;PPBP;CXCL6;...
Primary immunodeficiency -2.29 0.00e+0 33/38 (86.84%) CD8A;RFXANK;RAG2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H